World Library  
Flag as Inappropriate
Email this Article

Crohn's disease


Crohn's disease

Crohn's disease
Classification and external resources
The three most common sites of intestinal involvement in Crohn's disease are ileal, ileocolic and colonic.[1]
ICD-10 K50
ICD-9 555
OMIM 266600
DiseasesDB 3178
MedlinePlus 000249
eMedicine med/477 ped/507 radio/197
MeSH D003424

Crohn's disease, also known as Crohn syndrome and regional enteritis, is a type of inflammatory bowel disease (IBD) that may affect any part of the gastrointestinal tract from mouth to anus.[2] Symptoms often include: abdominal pain, diarrhea (which may be bloody if inflammation is severe), fever and weight loss.[1][2] Other complications may occur outside the gastrointestinal tract and include: anemia, skin rashes, arthritis, inflammation of the eye, and tiredness. The skin rashes may be due to infections as well as pyoderma gangrenosum or erythema nodosum. Bowel obstruction also commonly occurs and those with the disease are at greater risk of bowel cancer.[1] Crohn's disease is caused by a combination of environmental, immune and bacterial factors in genetically susceptible individuals.[3][4][5] It results in a chronic inflammatory disorder, in which the body's immune system attacks the gastrointestinal tract possibly directed at microbial antigens.[4][6] While Crohn's is an immune related disease, it does not appear to be an autoimmune disease (in that the immune system is not being triggered by the body itself).[7] The exact underlying immune problem is not clear; however, it may be an immunodeficiency state.[6][8][9] About half of the overall risk is related to genetics with more than 70 genes found to be involved.[1][10] Tobacco smokers are two times more likely to develop Crohn's disease than nonsmokers.[11] It also often begins after gastroenteritis. Diagnosis is based on a number of findings including: biopsy and appearance of the bowel wall, medical imaging and description of the disease. Other conditions that can present similarly include: irritable bowel syndrome and Behcet's disease.[1] There are no medications or surgical procedures that can cure Crohn's disease. Treatment options help with symptoms, maintain remission, and prevent relapse. In those newly diagnosed a corticosteroid may be used for a brief period of time to quickly improve the disease with another medication such as either methotrexate or a thiopurine used to prevent recurrence. An important part of treatment is the stopping of smoking among those who do. One in five people with the disease are admitted to hospital each year, and half of those with the disease will require surgery for the disease at some point over a ten year period. While surgery should be used as little as possible, it is necessary to address some abscesses, certain bowel obstructions, and cancers. Checking for bowel cancer via colonoscopy is recommended every few years, starting eight years after the disease has begun.[1] Crohn's disease affects about 3.2 per 1,000 people in Europe and North America.[12] It is less common in Asia and Africa.[13][14] It has historically been more common in the developed world.[15] Rates have, however, been increasing, particularly in the developing world since the 1970s.[14][15] Inflammatory bowel disease resulted in 35,000 deaths in 2010[16] and those with Crohn's disease have a slightly reduced life expectancy.[1] It tends to start in the teens and twenties, although it can occur at any age.[1][2] Males and females are equally affected.[2] The disease was named after gastroenterologist Burrill Bernard Crohn, who, in 1932, together with two other colleagues at Mount Sinai Hospital in New York, described a series of patients with inflammation of the terminal ileum of the small intestine, the area most commonly affected by the illness.[17]


  • Signs and symptoms 1
    • Gastrointestinal 1.1
    • Systemic 1.2
    • Extraintestinal 1.3
  • Cause 2
    • Genetics 2.1
    • Immune system 2.2
    • Microbes 2.3
    • Environmental factors 2.4
  • Pathophysiology 3
  • Diagnosis 4
    • Classification 4.1
    • Endoscopy 4.2
    • Radiologic tests 4.3
    • Blood tests 4.4
    • Comparison with ulcerative colitis 4.5
  • Management 5
    • Lifestyle changes 5.1
    • Medication 5.2
    • Surgery 5.3
    • Alternative medicine 5.4
  • Prognosis 6
    • Complications 6.1
  • Epidemiology 7
  • History 8
  • Research 9
  • References 10
  • External links 11

Signs and symptoms

Signs and symptoms
Crohn's disease Ulcerative colitis
Defecation Often porridge-like[18],
sometimes steatorrhea
Often mucus-like
and with blood[18]
Tenesmus Less common[18] More common[18]
Fever Common[18] Indicates severe disease[18]
Fistulae Common[19] Seldom
Weight loss Often More seldom


Patients with Crohn's can have aphthous ulcers involving mouth.

Many people with Crohn's disease have symptoms for years prior to the diagnosis.[20] The usual onset is between 15 and 30 years of age, but can occur at any age.[21] Because of the 'patchy' nature of the gastrointestinal disease and the depth of tissue involvement, initial symptoms can be more subtle than those of ulcerative colitis. People with Crohn's disease experience chronic recurring periods of flare-ups and remission.[22]

Abdominal pain may be the initial symptom of Crohn's disease. It is often accompanied by diarrhea, especially in those who have had surgery. The diarrhea may or may not be bloody. The nature of the diarrhea in Crohn's disease depends on the part of the small intestine or colon involved. Ileitis typically results in large-volume, watery feces. Colitis may result in a smaller volume of feces of higher frequency. Fecal consistency may range from solid to watery. In severe cases, an individual may have more than 20 bowel movements per day and may need to awaken at night to defecate.[1][23][24][25] Visible bleeding in the feces is less common in Crohn's disease than in ulcerative colitis, but may be seen in the setting of Crohn's colitis.[1] Bloody bowel movements typically come and go, and may be bright or dark red in color. In the setting of severe Crohn's colitis, bleeding may be copious.[23] Flatulence and bloating may also add to the intestinal discomfort.[23]

Symptoms caused by intestinal stenosis are also common in Crohn's disease. Abdominal pain is often most severe in areas of the bowel with stenoses. Persistent vomiting and nausea may indicate stenosis from small bowel obstruction or disease involving the stomach, pylorus, or duodenum.[23] Although the association is greater in the context of ulcerative colitis, Crohn's disease may also be associated with primary sclerosing cholangitis, a type of inflammation of the bile ducts.[26]

Perianal discomfort may also be prominent in Crohn's disease. Itchiness or pain around the anus may be suggestive of inflammation, fistulization or abscess around the anal area[1] or anal fissure. Perianal skin tags are also common in Crohn's disease.[27] Fecal incontinence may accompany perianal Crohn's disease. At the opposite end of the gastrointestinal tract, the mouth may be affected by non-healing sores (aphthous ulcers). Rarely, the esophagus, and stomach may be involved in Crohn's disease. These can cause symptoms including difficulty swallowing (dysphagia), upper abdominal pain, and vomiting.[28]


Crohn's disease, like many other chronic, inflammatory diseases, can cause a variety of systemic symptoms.[1] Among children, growth failure is common. Many children are first diagnosed with Crohn's disease based on inability to maintain growth.[29] As it may manifest at the time of the growth spurt in puberty, up to 30% of children with Crohn's disease may have retardation of growth.[30] Fever may also be present, though fevers greater than 38.5 ˚C (101.3 ˚F) are uncommon unless there is a complication such as an abscess.[1] Among older individuals, Crohn's disease may manifest as weight loss, usually related to decreased food intake, since individuals with intestinal symptoms from Crohn's disease often feel better when they do not eat and might lose their appetite.[29] People with extensive small intestine disease may also have malabsorption of carbohydrates or lipids, which can further exacerbate weight loss.[31]


Erythema nodosum on the back of a person with Crohn's disease

In addition to systemic and gastrointestinal involvement, Crohn's disease can affect many other organ systems.[32] Inflammation of the interior portion of the eye, known as uveitis, can cause blurred vision and eye pain, especially when exposed to light (photophobia).[33] Inflammation may also involve the white part of the eye (sclera), a condition called episcleritis.[33] Both episcleritis and uveitis can lead to loss of vision if untreated.

Crohn's disease that affects the ileum may result in an increased risk for gallstones. This is due to a decrease in bile acid resorption in the ileum and the bile gets excreted in the stool. As a result, the cholesterol/bile ratio increases in the gallbladder, resulting in an increased risk for gallstones.[33]

Crohn's disease is associated with a type of rheumatologic disease known as seronegative spondyloarthropathy.[33] This group of diseases is characterized by inflammation of one or more joints (arthritis) or muscle insertions (enthesitis).[33] The arthritis in Crohn's disease can be divided into two types. The first type affects larger weight-bearing joints such as the knee (most common), hips, shoulders, wrists, or elbows.[33] The second type symmetrically involves five or more of the small joints of the hands and feet.[33] The arthritis may also involve the spine, leading to ankylosing spondylitis if the entire spine is involved or simply sacroiliitis if only the sacroiliac joint is involved.[33] The symptoms of arthritis include painful, warm, swollen, stiff joints and loss of joint mobility or function.[22]

Pyoderma gangrenosum on the leg of a person with Crohn's disease

Crohn's disease may also involve the skin, blood, and endocrine system. The most common type of skin manifestation, erythema nodosum, presents as raised, tender red nodules usually appearing on the shins.[33][34] Erythema nodosum is due to inflammation of the underlying subcutaneous tissue, and is characterized by septal panniculitis.[34] Another skin lesion, pyoderma gangrenosum, is typically a painful ulcerating nodule. Crohn's disease also increases the risk of blood clots;[33] painful swelling of the lower legs can be a sign of deep venous thrombosis, while difficulty breathing may be a result of pulmonary embolism. Autoimmune hemolytic anemia, a condition in which the immune system attacks the red blood cells, is also more common in Crohn's disease and may cause fatigue, a pale appearance, and other symptoms common in anemia. Clubbing, a deformity of the ends of the fingers, may also be a result of Crohn's disease. Finally, Crohn's disease increases the risk of osteoporosis, or thinning of the bones.[33] Individuals with osteoporosis are at increased risk of bone fractures.[35]

People with Crohn's disease often have anemia due to vitamin B12, folate, iron deficiency, or due to anemia of chronic disease.[36][37] The most common is iron deficiency anemia[36] from chronic blood loss, reduced dietary intake, and persistent inflammation leading to increased hepcidin levels, restricting iron absorption in the duodenum.[37] As Crohn's disease most commonly affects the terminal ileum where the vitamin B12/intrinsic factor complex is absorbed, B12 deficiency may be seen.[37] This is particularly common after surgery to remove the ileum.[36] Involvement of the duodenum and jejunum can impair the absorption of many other nutrients including folate. If Crohn's disease affects the stomach, production of intrinsic factor can be reduced.

Crohn's disease can also cause neurological complications (reportedly in up to 15%).[38] The most common of these are seizures, stroke, myopathy, peripheral neuropathy, headache and depression.[38]

People with Crohn's often also have issues with small bowel bacterial overgrowth syndrome, which has similar symptoms.[39]

In the oral cavity people with Crohn's may develop cheilitis granulomatosa and other forms of orofacial granulomatosis, pyostomatitis vegetans, recurrent aphthous stomatitis, geographic tongue and migratory stomatitis in higher prevalence than the general population.[40]


Risk factors
Crohn's disease Ulcerative colitis
Smoking Higher risk for smokers Lower risk for smokers[41]
Age Usual onset between
15 and 30 years[42]
Peak incidence between
15 and 25 years

While the exact cause is unknown,[43] Crohn's disease seems to be due to a combination of environmental factors and genetic predisposition.[44] Crohn's is the first genetically complex disease in which the relationship between genetic risk factors and the immune system is understood in considerable detail.[45] Each individual risk mutation makes a small contribution to the overall risk of Crohn's (approximately 1:200). The genetic data, and direct assessment of immunity, indicates a malfunction in the innate immune system.[46] In this view, the chronic inflammation of Crohn's is caused when the adaptive immune system tries to compensate for a deficient innate immune system.[47]


NOD2 protein model with schematic diagram. Two N-terminal CARD domains (red) connected via helical linker (blue) with central NBD domain (green). At C-terminus LRR domain (cyan) is located. Additionally, some mutations which are associated with certain disease patterns in Crohn's disease are marked in red wire rpresentation.[48]

Crohn's has a genetic component.[49] Because of this, siblings of known people with Crohn's are 30 times more likely to develop Crohn's than the general population.

The first mutation found to be associated with Crohn's was a frameshift in the NOD2 gene (also known as the CARD15 gene),[50] followed by the discovery of point mutations.[51] Over thirty genes have been associated with Crohn's; a biological function is known for most of them. For example, one association is with mutations in the XBP1 gene, which is involved in the unfolded protein response pathway of the endoplasmatic reticulum.[52][53] Other well documented genes which increase the risk of developing Crohn disease are: ATG16L1,[54] IL23R,[55] IRGM,[56] and SLC11A1.[57] There is considerable overlap between susceptibility loci for IBD and mycobacterial infections.[58]

Immune system

There was a prevailing view that Crohn's disease is a primary T cell autoimmune disorder, however a newer theory hypothesizes that Crohn's results from an impaired innate immunity.[59] The later hypothesis describes impaired cytokine secretion by macrophages, which contributes to impaired innate immunity and leads to a sustained microbial-induced inflammatory response in the colon, where the bacterial load is high.[4][46] Another theory is that the inflammation of Crohn's was caused by an overactive Th1 and Th17 cytokine response.[60][61]

In 2007, the ATG16L1 gene has been implicated in Crohn's disease, which may induce autophagy and hinder the body's ability to attack invasive bacteria.[54] Another study has theorized that the human immune system traditionally evolved with the presence of parasites inside the body, and that the lack thereof due to modern hygiene standards has weakened the immune system. Test subjects were reintroduced to harmless parasites, with positive response.[62]


Current thinking is that mucosal layer and inability to clear bacteria from the intestinal walls, which are both symptoms of Crohn's.[63] Different strains found in tissue and different outcomes to antibiotics therapy and resistance suggest Crohn's Disease is not one disease, but an umbrella of diseases related to different pathogens.[64][65]

A number of studies have suggested a causal role for Mycobacterium avium subspecies paratuberculosis (MAP), which causes a similar disease, Johne's disease, in cattle.[66][67]

NOD2, a gene involved in Crohn's genetic susceptibility, is associated with diminished killing of MAP by macrophages, reduced innate and adaptive immunity in the host and impaired immune responses required for control of intracellular mycobacterial infection.[68] Macrophages infected with viable MAP are associated with high production of TNF-α.[69][70]

Other studies have linked specific strains of enteroadherent E. coli to the disease.[71] Adherent-invasive Escherichia coli (AIEC), are more common in people with CD,[72][73][74] have the ability to make strong biofilms compared to non-AIEC strains correlating with high adhesion and invasion indices[75][76] of neutrophils and the ability to block autophagy at the autolysosomal step, which allows for intracellular survival of the bacteria and induction of inflammation.[77] Inflammation drives the proliferation of AIEC and dysbiosis in the ileum, irrespective of genotype.[78] AIEC strains replicate extensively into macrophages inducing the secretion of very large amounts of TNF-α.[79]

Mouse studies have suggested some symptoms of Crohn's disease, ulcerative colitis and irritable bowel syndrome have the same underlying cause. Biopsy samples taken from the colons of all three patient groups were found to produce elevated levels of a serine protease.[80] Experimental introduction of the serine protease into mice has been found to produce widespread pain associated with irritable bowel syndrome, as well as colitis, which is associated with all three diseases.[81] Regional and temporal variations in those illnesses follow those associated with infection with the protozoan Blastocystis.[82]

The "cold-chain" hypothesis is that psychrotrophic bacteria such as Yersinia and Listeria species contribute to the disease. A statistical correlation was found between the advent of the use of refrigeration in the United States and various parts of Europe and the rise of the disease.[83][84][85]

There is an apparent connection between Crohn's disease, Mycobacterium, other pathogenic bacteria, and genetic markers.[86][87] In many individuals, genetic factors predispose individuals to Mycobacterium avium subsp. paratuberculosis infection. This bacterium then produces mannins, which protect both itself and various bacteria from phagocytosis, which causes a variety of secondary infections.[88]

Still, this relationship between specific types of bacteria and Crohn's disease remains unclear.[89][90]

Environmental factors

The increased incidence of Crohn's in the industrialized world indicates an environmental component. Crohn's is associated with an increased intake of animal protein, milk protein and an increased ratio of omega-6 to omega-3 polyunsaturated fatty acids.[91] Those who consume vegetable proteins appear to have a lower incidence of Crohn's disease. Consumption of fish protein has no association.[91] Smoking increases the risk of the return of active disease (flares).[11] The introduction of hormonal contraception in the United States in the 1960s is associated with a dramatic increase in incidence, and one hypothesis is that these drugs work on the digestive system in ways similar to smoking.[92] Isotretinoin is associated with Crohn's.[93][94][95] Although stress is sometimes claimed to exacerbate Crohn's disease, there is no concrete evidence to support such claim.[96] Dietary microparticles, such as those found in toothpaste, have been studied as they produce effects on immunity, but they were not consumed in greater amounts in patients with Crohn's.[97][98]


Crohn's disease Ulcerative colitis
Cytokine response Associated with Th17[61] Vaguely associated with Th2

During a colonoscopy, biopsies of the colon are often taken to confirm the diagnosis. Certain characteristic features of the pathology seen point toward Crohn's disease; it shows a transmural pattern of inflammation, meaning the inflammation may span the entire depth of the intestinal wall.[1] Ulceration is an outcome seen in highly active disease. There is usually an abrupt transition between unaffected tissue and the ulcer - a characteristic sign known as skip lesions. Under a microscope, biopsies of the affected colon may show mucosal inflammation, characterized by focal infiltration of neutrophils, a type of inflammatory cell, into the epithelium. This typically occurs in the area overlying lymphoid aggregates. These neutrophils, along with mononuclear cells, may infiltrate the crypts, leading to inflammation (crypititis) or abscess (crypt abscess). Granulomas, aggregates of macrophage derivatives known as giant cells, are found in 50% of cases and are most specific for Crohn's disease. The granulomas of Crohn's disease do not show "caseation", a cheese-like appearance on microscopic examination characteristic of granulomas associated with infections, such as tuberculosis. Biopsies may also show chronic mucosal damage, as evidenced by blunting of the intestinal villi, atypical branching of the crypts, and a change in the tissue type (metaplasia). One example of such metaplasia, Paneth cell metaplasia, involves development of Paneth cells (typically found in the small intestine and a key regulator of intestinal microbiota) in other parts of the gastrointestinal system.[99][100]


The diagnosis of Crohn's disease can sometimes be challenging,[20] and a number of tests are often required to assist the physician in making the diagnosis.[23] Even with a full battery of tests, it may not be possible to diagnose Crohn's with complete certainty; a colonoscopy is approximately 70% effective in diagnosing the disease, with further tests being less effective. Disease in the small bowel is particularly difficult to diagnose, as a traditional colonoscopy allows access to only the colon and lower portions of the small intestines; introduction of the capsule endoscopy[101] aids in endoscopic diagnosis. Multinucleated giant cells, a common finding in the lesions of Crohn's disease, are less common in the lesions of lichen nitidus.[102]


Distribution of gastrointestinal Crohn's disease.

Crohn's disease is one type of inflammatory bowel disease (IBD). It typically manifests in the gastrointestinal tract and can be categorized by the specific tract region affected. A disease of both the ileum (the last part of the small intestine that connects to the large intestine), and the large intestine, Ileocolic Crohn's accounts for fifty percent of cases. Crohn's ileitis, manifest in the ileum only, accounts for thirty percent of cases, while Crohn's colitis, of the large intestine, accounts for the remaining twenty percent of cases and may be particularly difficult to distinguish from ulcerative colitis. Gastroduodenal Crohn's disease causes inflammation in the stomach and first part of the small intestine, called the duodenum. Jejunoileitis causes spotty patches of inflammation in the top half of the small intestine, called the jejunum.[103] The disease can attack any part of the digestive tract, from mouth to anus. However, individuals affected by the disease rarely fall outside these three classifications, with presentations in other areas.[1]

Crohn's disease may also be categorized by the behavior of disease as it progresses. These categorizations formalized in the Vienna classification of the disease.[104] There are three categories of disease presentation in Crohn's disease: stricturing, penetrating, and inflammatory. Stricturing disease causes narrowing of the bowel that may lead to bowel obstruction or changes in the caliber of the feces. Penetrating disease creates abnormal passageways (fistulae) between the bowel and other structures, such as the skin. Inflammatory disease (or nonstricturing, nonpenetrating disease) causes inflammation without causing strictures or fistulae.[104][105]


A colonoscopy is the best test for making the diagnosis of Crohn's disease, as it allows direct visualization of the colon and the terminal ileum, identifying the pattern of disease involvement. On occasion, the colonoscope can travel past the terminal ileum, but it varies from person to person. During the procedure, the gastroenterologist can also perform a biopsy, taking small samples of tissue for laboratory analysis, which may help confirm a diagnosis. As 30% of Crohn's disease involves only the ileum,[1] cannulation of the terminal ileum is required in making the diagnosis. Finding a patchy distribution of disease, with involvement of the colon or ileum, but not the rectum, is suggestive of Crohn's disease, as are other endoscopic stigmata.[106] The utility of capsule endoscopy for this, however, is still uncertain.[107] A "cobblestone"-like appearance is seen in approximately 40% of cases of Crohn's disease upon colonoscopy, representing areas of ulceration separated by narrow areas of healthy tissue.

Radiologic tests

A small bowel follow-through may suggest the diagnosis of Crohn's disease and is useful when the disease involves only the small intestine. Because colonoscopy and gastroscopy allow direct visualization of only the terminal ileum and beginning of the duodenum, they cannot be used to evaluate the remainder of the small intestine. As a result, a barium follow-through X-ray, wherein barium sulfate suspension is ingested and fluoroscopic images of the bowel are taken over time, is useful for looking for inflammation and narrowing of the small bowel.[106][108] Barium enemas, in which barium is inserted into the rectum and fluoroscopy is used to image the bowel, are rarely used in the work-up of Crohn's disease due to the advent of colonoscopy. They remain useful for identifying anatomical abnormalities when strictures of the colon are too small for a colonoscope to pass through, or in the detection of colonic fistulae (in this case contrast should be performed with iodate substances).[109]

CT and MRI scans are useful for evaluating the small bowel with enteroclysis protocols.[110] They are also useful for looking for intra-abdominal complications of Crohn's disease, such as abscesses, small bowel obstructions, or fistulae.[111] Magnetic resonance imaging (MRI) is another option for imaging the small bowel as well as looking for complications, though it is more expensive and less readily available[112]

Blood tests

A complete blood count may reveal anemia, which commonly is caused by blood loss leading to iron deficiency (a microcytic anemia) or by vitamin B12 deficiency (a macrocytic anemia), usually caused by ileal disease impairing vitamin B12 absorption. Rarely autoimmune hemolysis may occur.[113] Ferritin levels help assess if iron deficiency is contributing to the anemia. Erythrocyte sedimentation rate (ESR) and C-reactive protein help assess the degree of inflammation, which is important as ferritin can also be raised in inflammation.[114] Serum iron, total iron binding capacity and transferrin saturation may be more easily interpreted in inflammation. Anemia of chronic disease results in a normocytic anemia. Other causes of anemia include medication used in treatment of inflammatory bowel disease, like azathioprine, which can lead to cytopenia, and sulfasalazine, which can also result in folate deficiency. Testing for Saccharomyces cerevisiae antibodies (ASCA) and antineutrophil cytoplasmic antibodies (ANCA) has been evaluated to identify inflammatory diseases of the intestine[115] and to differentiate Crohn's disease from ulcerative colitis.[116] Furthermore, increasing amounts and levels of serological antibodies such as ASCA, antilaminaribioside [Glc(β1,3)Glb(β); ALCA], antichitobioside [GlcNAc(β1,4)GlcNAc(β); ACCA], antimannobioside [Man(α1,3)Man(α)AMCA], antiLaminarin [(Glc(β1,3))3n(Glc(β1,6))n; anti-L] and antichitin [GlcNAc(β1,4)n; anti-C] associate with disease behavior and surgery, and may aid in the prognosis of Crohn's disease.[117][118][119][120]

Comparison with ulcerative colitis

The most common disease that mimics the symptoms of Crohn's disease is ulcerative colitis, as both are inflammatory bowel diseases that can affect the colon with similar symptoms. It is important to differentiate these diseases, since the course of the diseases and treatments may be different. In some cases, however, it may not be possible to tell the difference, in which case the disease is classified as indeterminate colitis.[1][23][24]
Diagnostic findings
Crohn's disease Ulcerative colitis
Terminal ileum involvement Commonly Seldom
Colon involvement Usually Always
Rectum involvement Seldom Usually[41]
Involvement around
the anus
Common[19] Seldom
Bile duct involvement No increase in rate of primary sclerosing cholangitis Higher rate[121]
Distribution of Disease Patchy areas of inflammation (Skip lesions) Continuous area of inflammation[41]
Endoscopy Deep geographic and serpiginous (snake-like) ulcers Continuous ulcer
Depth of inflammation May be transmural, deep into tissues[122][19] Shallow, mucosal
Stenosis Common Seldom
Granulomas on biopsy May have non-necrotizing non-peri-intestinal crypt granulomas[19][123][124] Non-peri-intestinal crypt granulomas not seen[41]


Crohn's disease Ulcerative colitis
Mesalazine Less useful[125] More useful[125]
Antibiotics Effective in long-term[126] Generally not useful[127]
Surgery Often returns following
removal of affected part
Usually cured by removal
of colon

There is no cure for Crohn's disease and remission may not be possible or prolonged if achieved. In cases where remission is possible, relapse can be prevented and symptoms controlled with medication, lifestyle and dietary changes, changes to eating habits (eating smaller amounts more often), reduction of stress, moderate activity and exercise. Surgery is generally contraindicated and has not been shown to prevent remission. Adequately controlled, Crohn's disease may not significantly restrict daily living.[128] Treatment for Crohn's disease is only when symptoms are active and involve first treating the acute problem, then maintaining remission.

Lifestyle changes

Certain lifestyle changes can reduce symptoms, including dietary adjustments, elemental diet, proper hydration, and smoking cessation. Smoking may increase Crohn's disease; stopping is recommended. Eating small meals frequently instead of big meals may also help with a low appetite. To manage symptoms have a balanced diet with proper portion control. Fatigue can be helped with regular exercise, a healthy diet, and enough sleep. A food diary may help with identifying foods that trigger symptoms. Some people should follow a low dietary fiber diet to control symptoms especially if fibrous foods cause symptoms.[128] Some find relief in eliminating casein (protein found in cow's milk) and gluten (protein found in wheat, rye and barley) from their diets. They may have specific dietary intolerances (not allergies).[129]


Acute treatment uses medications to treat any infection (normally antibiotics) and to reduce inflammation (normally aminosalicylate anti-inflammatory drugs and corticosteroids). When symptoms are in remission, treatment enters maintenance, with a goal of avoiding the recurrence of symptoms. Prolonged use of corticosteroids has significant side-effects; as a result, they are, in general, not used for long-term treatment. Alternatives include aminosalicylates alone, though only a minority are able to maintain the treatment, and many require immunosuppressive drugs.[19] It has been also suggested that antibiotics change the enteric flora, and their continuous use may pose the risk of overgrowth with pathogens such as Clostridium difficile.[130]

Medications used to treat the symptoms of Crohn's disease include 5-aminosalicylic acid (5-ASA) formulations, prednisone, immunomodulators such as azathioprine (given as the prodrug for 6-mercaptopurine), methotrexate, infliximab, adalimumab,[24] certolizumab[131] and natalizumab.[132][133] Hydrocortisone should be used in severe attacks of Crohn's disease.[134]

The gradual loss of blood from the gastrointestinal tract, as well as chronic inflammation, often leads to anemia, and professional guidelines suggest routinely monitoring for this.[135][136][137] Adequate disease control usually improves anemia of chronic disease, but iron deficiency may require treatment with iron supplements. Guidelines vary as to how iron should be administered. Some[137] advise parenteral iron as first line as it works faster, has fewer gastrointestinal side effects, and is unaffected by inflammation reducing enteral absorption.

Other guidelines[136] advise oral iron as first line with parenteral iron reserved for those that fail to adequately respond as oral iron is considerably cheaper. All agree that severe anemia (hemoglobin under 10g/dL) should be treated with parenteral iron. Blood transfusion should be reserved for those who are cardiovascularly unstable, due the relatively poor safety profile, lack of long term efficacy, and cost.[136]


Crohn's cannot be cured by surgery, though it is used in the case of partial or full blockage of the intestine. Surgery may also be required for complications such as obstructions, fistulas, or abscesses, or if the disease does not respond to drugs. After the first surgery, Crohn's usually shows up at the site of the resection, however it can appear in other locations. After a resection, scar tissue builds up, which can cause strictures, which form when the intestines become too small to allow excrement to pass through easily, which can lead to a blockage. After the first resection, another resection may be necessary within five years.[138] For patients with an obstruction due to a stricture, two options for treatment are strictureplasty and resection of that portion of bowel. There is no statistical significance between strictureplasty alone versus strictureplasty and resection in cases of duodenal involvement. In these cases, re-operation rates were 31% and 27%, respectively, indicating that strictureplasty is a safe and effective treatment for selected people with duodenal involvement.[139]

Postsurgical recurrence of Crohn's disease is relatively common. Crohn's lesions are often found at the site of the resected bowel. The join (or anastomosis) after surgery may be inspected, usually during a colonoscopy, and disease activity graded. The "Rutgeert's score" is an endoscopic scoring system for post-operative disease recurrence in Crohn's disease.[140] Fewer lesions result in a lower grade. Based on the score, treatment plans can be designed to give the patient the best chance of managing recurrence of the disease.[141]

Short bowel syndrome (SBS, also short gut syndrome or simply short gut) is caused by the surgical removal of part of the small intestine. It usually develops in those patients who have had half or more of their small intestines removed.[142] Diarrhea is the main symptom, but others may include weight loss, cramping, bloating, and heartburn. Short bowel syndrome is treated with changes in diet, intravenous feeding, vitamin and mineral supplements, and treatment with medications.

Bile acid diarrhea is another complication following surgery for Crohn's disease in which the terminal ileum has been removed. This leads to the development of excessive watery diarrhea. It is usually thought to be due to an inability of the ileum to reabsorb bile acids after resection of the terminal ileum and was the first type of bile acid malabsorption recognized.[143]

In some cases of SBS, intestinal transplant surgery may be considered; though the number of transplant centres offering this procedure is quite small and it comes with a high risk due to the chance of infection and rejection of the transplanted intestine.[144]

Alternative medicine

More than half of people with Crohn's disease have tried complementary or alternative therapy.[145] These include diets, probiotics, fish oil and other herbal and nutritional supplements. Some scientists have suggested more research into these is needed to discriminate between effective therapies and "pseudo" therapies that can be ineffective.[146]

  • Acupuncture is used to treat inflammatory bowel disease in China, and is being used more frequently in Western society.[147] There is insufficient evidence to recommend the use of acupuncture.[148] Acupuncture also increases the risk of infection.[149]
  • Homeopathy is frequently used in Germany as a treatment for Crohn's disease, though no clinical trials exist that demonstrate homeopathy is effective.[150]


Crohn's disease is a chronic condition for which there is no cure. It is characterised by periods of improvement followed by episodes when symptoms flare up. With treatment, most people achieve a healthy weight, and the mortality rate for the disease is relatively low. It can vary from being benign to very severe and people with CD could experience just one episode or have continuous symptoms. It usually reoccurs, although some people can remain disease free for years or decades. Most people with Crohn's live a normal lifespan.[151] However, Crohn's disease is associated with a small increase in risk of small bowel and colorectal carcinoma (bowel cancer).[152]
Nutrient deficiency Higher risk
Colon cancer risk Slight Considerable
Prevalence of extraintestinal complications[153]
Iritis/uveitis Females 2.2% 3.2%
Males 1.3% 0.9%
Primary sclerosing
Females 0.3% 1%
Males 0.4% 3%
Females 0.7% 0.8%
Males 2.7% 1.5%
Females 1.2% 0.8%
Males 1.3% 0.7%
Erythema nodosum Females 1.9% 2%
Males 0.6% 0.7%


Crohn's disease can lead to several mechanical complications within the intestines, including obstruction, fistulae, and abscesses.

Obstruction typically occurs from strictures or adhesions that narrow the lumen, blocking the passage of the intestinal contents.

Fistulae can develop between two loops of bowel, between the bowel and bladder, between the bowel and vagina, and between the bowel and skin.

Abscesses are walled off collections of infection, which can occur in the abdomen or in the perianal area.

Crohn's is responsible for 10% of vesicoenteric fistulae, and is the most common cause of ileovesical fistulae.[154]

Endoscopic image of colon cancer identified in the sigmoid colon on screening colonoscopy for Crohn's disease

Crohn's disease also increases the risk of cancer in the area of inflammation. For example, individuals with Crohn's disease involving the small bowel are at higher risk for small intestinal cancer. Similarly, people with Crohn's colitis have a relative risk of 5.6 for developing colon cancer.[155] Screening for colon cancer with colonoscopy is recommended for anyone who has had Crohn's colitis for at least eight years.[156] Some studies suggest there is a role for chemoprotection in the prevention of colorectal cancer in Crohn's involving the colon; two agents have been suggested, folate and mesalamine preparations.[157]

Individuals with Crohn's disease are at risk of malnutrition for many reasons, including decreased food intake and malabsorption. The risk increases following resection of the small bowel. Such individuals may require oral supplements to increase their caloric intake, or in severe cases, total parenteral nutrition (TPN). Most people with moderate or severe Crohn's disease are referred to a dietitian for assistance in nutrition.[158]

The major significant complications of Crohn's disease, including bowel obstruction, abscesses, free perforation and hemorrhage,[159] in rare cases,[160] may be fatal.[161]

Crohn's disease can be problematic during pregnancy, and some medications can cause adverse outcomes for the fetus or mother. Consultation with an obstetrician and gastroenterologist about Crohn's disease and all medications facilitates preventative measures. In some cases, remission occurs during pregnancy. Certain medications can also lower sperm count or otherwise adversely affect a man's fertility.[162]


The percentage of people with Crohn's disease has been determined in Norway and the United States and is similar at 6 to 7.1:100,000. The Crohn's and Colitis Foundation of America cites this number as approx 149:100,000; NIH cites 28 to 199 per 100,000.[163][164] Crohn's disease is more common in northern countries, and with higher rates still in the northern areas of these country.[165] The incidence of Crohn's disease is thought to be similar in Europe but lower in Asia and Africa.[163] It also has a higher incidence in Ashkenazi Jews[1][166] and smokers.[167]

Crohn's disease begins most commonly in people in their teens and 20s, and people in their 50s through to their 70s.[1][23] It is rarely diagnosed in early childhood. It usually affects females children more severely than males.[168] However, only slightly more women than men have Crohn's disease.[169] Parents, siblings or children of people with Crohn's disease are 3 to 20 times more likely to develop the disease.[170] Twin studies find that if one has the disease there is a 55% chance the other will too.[171]


Inflammatory bowel diseases were described by T. Kennedy Dalziel in 1913.[172]

Ileitis terminalis was first described by Polish surgeon Antoni Leśniowski in 1904, however, due to the precedence of Crohn's name in the alphabet, it later became known in the worldwide literature as Crohn's disease.[173] Only in Poland is it still called Leśniowski-Crohn's disease. Burrill Bernard Crohn, an American gastroenterologist at New York City's Mount Sinai Hospital, described fourteen cases in 1932, and submitted them to the American Medical Association under the rubric of "Terminal ileitis: A new clinical entity". Later that year, he, along with colleagues Leon Ginzburg and Gordon Oppenheimer published the case series as "Regional ileitis: a pathologic and clinical entity".[17]


Some evidence supports the hypothesis that the bacterium Mycobacterium avium subspecies paratuberculosis (MAP) is a cause of Crohn’s disease (see also Johne's disease). As a result, researchers are looking at the eradication of MAP as a therapeutic option.[174] Treating MAP using antibiotics has been examined and the results are unclear but tentatively beneficial.[175][176] Vaccination against MAP is also being studied. An anti-MAP vaccine appears effective in mice and cattle with MAP with no apparent side effects.[174][177] Trials in human are pending.[178]

Recent studies using helminthic therapy or hookworms to treat Crohn's Disease and other (non-viral) auto-immune diseases seem to yield promising results.[179]

Numerous preclinical studies demonstrate that activation of the CB1 and CB2 cannabinoid receptors exert biological functions on the gastrointestinal tract.[180] Activation of CB1 and CB2 receptors in animals has shown a strong anti-inflammatory effect.[181] Cannabinoids and/or modulation of the endocannabinoid system is a novel therapeutic means for the treatment of numerous GI disorders, including inflammatory bowel diseases like Crohn's disease.[182]

There is no good evidence that thalidomide or lenalidomide is useful to bring about or maintain remission.[183][184]


  1. ^ a b c d e f g h i j k l m n o p q r s Baumgart DC, Sandborn WJ; Sandborn (2012). "Crohn's disease". The Lancet 380 (9853): 1590–605.  
  2. ^ a b c d "Crohn's Disease". National Digestive Diseases Information Clearinghouse (NDDIC). July 10, 2013. Retrieved 12 June 2014. 
  3. ^ Cho JH, Brant SR (2011). "Recent Insights into the Genetics of Inflammatory Bowel Disease". Gastroenterology 140 (6): 1704–12.  
  4. ^ a b c Dessein R, Chamaillard M, Danese S (2008). "Innate Immunity in Crohnʼs Disease". Journal of Clinical Gastroenterology 42: S144–7.  
  5. ^ Stefanelli T, Malesci A, Repici A, Vetrano S, Danese S (2008). "New Insights into Inflammatory Bowel Disease Pathophysiology: Paving the Way for Novel Therapeutic Targets". Current Drug Targets 9 (5): 413–8.  
  6. ^ a b Marks DJ, Rahman FZ, Sewell GW, Segal AW (2010). "Crohn's disease: An immune deficiency state". Clinical reviews in allergy & immunology 38 (1): 20–31.  
  7. ^ Casanova JL, Abel L (Aug 31, 2009). "Revisiting Crohn's disease as a primary immunodeficiency of macrophages.". The Journal of experimental medicine 206 (9): 1839–43.  
  8. ^ Lalande JD, Behr MA (2010). "Mycobacteria in Crohn's disease: How innate immune deficiency may result in chronic inflammation". Expert review of clinical immunology 6 (4): 633–41.  
  9. ^ Yamamoto-Furusho JK, Korzenik JR (2006). "Crohn's disease: Innate immunodeficiency?". World Journal of Gastroenterology 12 (42): 6751–5.  
  10. ^ a b Cosnes J (2004). "Tobacco and IBD: Relevance in the understanding of disease mechanisms and clinical practice". Best Practice & Research Clinical Gastroenterology 18 (3): 481–96.  
  11. ^ Molodecky, NA; Soon, IS; Rabi, DM; Ghali, WA; Ferris, M; Chernoff, G; Benchimol, EI; Panaccione, R; Ghosh, S; Barkema, HW; Kaplan, GG (Jan 2012). "Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review.". Gastroenterology 142 (1): 46–54.e42; quiz e30.  
  12. ^ Prideaux, L; Kamm, MA; De Cruz, PP; Chan, FK; Ng, SC (Aug 2012). "Inflammatory bowel disease in Asia: a systematic review.". Journal of Gastroenterology and Hepatology 27 (8): 1266–80.  
  13. ^ a b Hovde, Ø; Moum, BA (Apr 21, 2012). "Epidemiology and clinical course of Crohn's disease: results from observational studies.". World journal of gastroenterology : WJG 18 (15): 1723–31.  
  14. ^ a b Burisch, J; Munkholm, P (Jul 2013). "Inflammatory bowel disease epidemiology.". Current opinion in gastroenterology 29 (4): 357–62.  
  15. ^ Lozano, R; Naghavi, M (Dec 15, 2012). "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.". Lancet 380 (9859): 2095–128.  
  16. ^ a b Crohn BB, Ginzburg L, Oppenheimer GD (2000). "Regional ileitis: A pathologic and clinical entity. 1932". The Mount Sinai journal of medicine, New York 67 (3): 263–8.  
  17. ^ a b c d e f > Inflammatorisk tarmsjukdom, kronisk, IBD By Robert Löfberg. Retrieved Oct 2010 Translate.
  18. ^ a b c d e Hanauer SB, Sandborn W (2001-03-01). "Management of Crohn's disease in adults" (PDF). American Journal of Gastroenterology 96 (3): 635–43.  
  19. ^ a b Pimentel M, Chang M, Chow EJ, Tabibzadeh S, Kirit-Kiriak V, Targan SR, Lin HC (2000). "Identification of a prodromal period in Crohn's disease but not ulcerative colitis". The American Journal of Gastroenterology 95 (12): 3458–62.  
  20. ^ Crohn's Disease Overview
  21. ^ a b Zieve, David; George F Longstreth (October 18, 2009). "Crohn's Disease". ADAM Health Illustrated Encyclopedia. Retrieved 2010-08-16. 
  22. ^ a b c d e f g Crohn Disease at eMedicine
  23. ^ a b c Podolsky DK (2002). "Inflammatory Bowel Disease". New England Journal of Medicine 347 (6): 417–29.  
  24. ^ Mueller MH, Kreis ME, Gross ML, Becker HD, Zittel TT, Jehle EC (2002). "Anorectal functional disorders in the absence of anorectal inflammation in patients with Crohn's disease". British Journal of Surgery 89 (8): 1027–31.  
  25. ^ Kumar, Vinay; Abbas, Abul K.; Fausto, Nelson (July 30, 2004). "The Gastrointestinal Tract". Robbins and Cotran: Pathologic Basis of Disease (7th ed.). Philadelphia, Pennsylvania: Elsevier Saunders. p. 847.  
  26. ^ Taylor BA, Williams GT, Hughes LE, Rhodes J (1989). "The histology of anal skin tags in Crohn's disease: An aid to confirmation of the diagnosis". International Journal of Colorectal Disease 4 (3): 197–9.  
  27. ^ Fix OK, Soto JA, Andrews CW, Farraye FA (2004). "Gastroduodenal Crohn's disease". Gastrointestinal Endoscopy 60 (6): 985.  
  28. ^ a b Beattie RM, Croft NM, Fell JM, Afzal NA, Heuschkel RB (2006). "Inflammatory bowel disease". Archives of Disease in Childhood 91 (5): 426–32.  
  29. ^ Büller HA (1997). "Problems in diagnosis of IBD in children". The Netherlands Journal of Medicine 50 (2): S8–11.  
  30. ^ O'Keefe SJ (1996). "Nutrition and gastrointestinal disease". Scand. J. Gastroenterol. Suppl. 220: 52–9.  
  31. ^ Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, Fedeli G, Gasbarrini G, Gasbarrini A (2005). "Extraintestinal manifestations in inflammatory bowel disease". World Journal of Gastroenterology 11 (46): 7227–36.  
  32. ^ a b c d e f g h i j k Trikudanathan G, Venkatesh PG, Navaneethan U (2012). "Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease". Drugs 72 (18): 2333–49.  
  33. ^ a b Thrash B, Patel M, Shah KR, Boland CR, Menter A (2013). "Cutaneous manifestations of gastrointestinal disease: part II". Journal of the American Academy of Dermatology 68 (2): 211 e1–33.  
  34. ^ Bernstein M, Irwin S, Greenberg GR (2005). "Maintenance Infliximab Treatment is Associated with Improved Bone Mineral Density in Crohn's Disease". The American Journal of Gastroenterology 100 (9): 2031–5.  
  35. ^ a b c Lomer MC (August 2011). "Dietary and nutritional considerations for inflammatory bowel disease". The Proceedings of the Nutrition Society 70 (3): 329–35.  
  36. ^ a b c Gerasimidis K, McGrogan P, Edwards CA (August 2011). "The aetiology and impact of malnutrition in paediatric inflammatory bowel disease". Journal of Human Nutrition and Dietetics 24 (4): 313–26.  
  37. ^ a b Crohn's disease. Retrieved July 13, 2007.
  38. ^ MedlinePlus Encyclopedia Small bowel bacterial overgrowth
  39. ^ Zadik Y, Drucker S, Pallmon S (2011). "Migratory stomatitis (ectopic geographic tongue) on the floor of the mouth". Journal of the American Academy of Dermatology 65 (2): 459–60.  
  40. ^ a b c d Kornbluth A, Sachar DB (July 2004). "Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee". American Journal of Gastroenterology 99 (7): 1371–85.  
  41. ^ Crohn's Disease Overview
  42. ^ "Crohn's diseaseShare on facebookShare on twitterBookmark & SharePrinter-friendly version". 2013-10-13. Retrieved 16 September 2014. 
  43. ^ Braat H, Peppelenbosch MP, Hommes DW (August 2006). "Immunology of Crohn's disease". Annals of the New York Academy of Sciences 1072: 135–54.  
  44. ^ Henckaerts L, Figueroa C, Vermeire S, Sans M (May 2008). "The role of genetics in inflammatory bowel disease". Curr Drug Targets 9 (5): 361–8.  
  45. ^ a b Marks DJ, Harbord MW, MacAllister R, Rahman FZ, Young J, Al-Lazikani B, Lees W, Novelli M, Bloom S, Segal AW (2006). "Defective acute inflammation in Crohn's disease: a clinical investigation". Lancet 367 (9511): 668–78.  
  46. ^ Comalada M, Peppelenbosch MP (September 2006). "Impaired innate immunity in Crohn's disease". Trends Mol Med 12 (9): 397–9.  
  47. ^ Nakagome, S.; Mano, S.; Kozlowski, L.; Bujnicki, JM.; Shibata, H.; Fukumaki, Y.; Kidd, JR.; Kidd, KK. et al. (Jun 2012). "Crohn's disease risk alleles on the NOD2 locus have been maintained by natural selection on standing variation.". Mol Biol Evol 29 (6): 1569–85.  
  48. ^ "Crohn's disease has strong genetic link: study".  
  49. ^ Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nuñez G, Cho JH (2001). "A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease". Nature 411 (6837): 603–6.  
  50. ^ Cuthbert AP, Fisher SA, Mirza MM, King K, Hampe J, Croucher PJ, Mascheretti S, Sanderson J, Forbes A, Mansfield J, Schreiber S, Lewis CM, Mathew CG (2002). "The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease". Gastroenterology 122 (4): 867–74.  
  51. ^ Kaser A, Lee AH, Franke A, Glickman JN, Zeissig S, Tilg H, Nieuwenhuis EE, Higgins DE, Schreiber S, Glimcher LH, Blumberg RS (5 September 2008). "XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease". Cell 134 (5): 743–56.  
  52. ^ Clevers H (2009). "Inflammatory Bowel Disease, Stress, and the Endoplasmic Reticulum".  
  53. ^ a b Prescott NJ, Fisher SA, Franke A, Hampe J, Onnie CM, Soars D, Bagnall R, Mirza MM, Sanderson J, Forbes A, Mansfield JC, Lewis CM, Schreiber S, Mathew CG (2007). "A nonsynonymous SNP in ATG16L1 predisposes to ileal Crohn's disease and is independent of CARD15 and IBD5". Gastroenterology 132 (5): 1665–71.  
  54. ^ Diegelmann, J.; Czamara, D.; Le Bras, E.; Zimmermann, E.; Olszak, T.; Bedynek, A.; Göke, B.; Franke, A. et al. (2013). "Intestinal DMBT1 expression is modulated by Crohn's disease-associated IL23R variants and by a DMBT1 variant which influences binding of the transcription factors CREB1 and ATF-2.". PLOS ONE 8 (11): e77773.  
  55. ^ Prescott, NJ.; Dominy, KM.; Kubo, M.; Lewis, CM.; Fisher, SA.; Redon, R.; Huang, N.; Stranger, BE. et al. (May 2010). "Independent and population-specific association of risk variants at the IRGM locus with Crohn's disease.". Hum Mol Genet 19 (9): 1828–39.  
  56. ^ Chermesh, I.; Azriel, A.; Alter-Koltunoff, M.; Eliakim, R.; Karban, A.; Levi, BZ. (Jul 2007). "Crohn's disease and SLC11A1 promoter polymorphism.". Dig Dis Sci 52 (7): 1632–5.  
  57. ^ Jostins L, Ripke S, Weersma RK, et al. (2012). "Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease". Nature 491 (7422): 119–24.  
  58. ^ Marks DJ, Segal AW (January 2008). "Innate immunity in inflammatory bowel disease: a disease hypothesis". J Pathol. 214 (2): 260–6.  
  59. ^ Cobrin GM, Abreu MT (2005). "Defects in mucosal immunity leading to Crohn's disease". Immunol. Rev. 206: 277–95.  
  60. ^ a b Elson CO, Cong Y, Weaver CT, Schoeb TR, McClanahan TK, Fick RB, Kastelein RA (2007). "Monoclonal Anti – Interleukin 23 Reverses Active Colitis in a T Cell – Mediated Model in Mice". Gastroenterology 132 (7): 2359–70.  
  61. ^ Moises Velasquez-Manoff (June 29, 2008). "The Worm Turns".  
  62. ^ Sartor, R Balfour (2006). "Mechanisms of Disease: Pathogenesis of Crohn's disease and ulcerative colitis". Nature Clinical Practice Gastroenterology & Hepatology 3 (7): 390.  
  63. ^ Dogan B, Scherl E, Bosworth B, Yantiss R, Altier C, McDonough PL, Jiang ZD, Dupont HL, Garneau P, Harel J, Rishniw M, Simpson KW (2013). "Multidrug resistance is common in Escherichia coli associated with ileal Crohn's disease". Inflamm. Bowel Dis. 19 (1): 141–50.  
  64. ^ Campbell, Jordana (2012). "The many faces of Crohn’s Disease: Latest concepts in etiology". Open Journal of Internal Medicine 02 (02): 107–115.  
  65. ^ Naser SA, Collins MT (December 2005). "Debate on the lack of evidence of Mycobacterium avium subsp. paratuberculosis in Crohn's disease". Inflamm. Bowel Dis. 11 (12): 1123.  
  66. ^ Naser SA, Sagramsingh SR, Naser AS, and Naser ST (June 2014). "Mycobacterium avium subspecies paratuberculosis causes Crohn's disease in some inflammatory bowel disease patients". World J Gastroenterol. 20 (23): 7403–7415.  
  67. ^ Glubb DM, Gearry RB, Barclay ML, Roberts RL, Pearson J, Keenan JI, McKenzie J, Bentley RW (2011). polymorphisms affect monocyte responses in Crohn's disease"ATG16L1 and NOD2". World Journal of Gastroenterology 17 (23): 2829–37.  
  68. ^ Clancy R, Ren Z, Turton J, Pang G, Wettstein A (2007). "Molecular evidence for Mycobacterium avium subspecies paratuberculosis (MAP) in Crohn's disease correlates with enhanced TNF-alpha secretion". Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 39 (5): 445–51.  
  69. ^ Nakase H, Tamaki H, Matsuura M, Chiba T, Okazaki K (2011). "Involvement of mycobacterium avium subspecies paratuberculosis in TNF-α production from macrophage: Possible link between MAP and immune response in Crohn's disease". Inflammatory bowel diseases 17 (11): E140–2.  
  70. ^ Baumgart M, Dogan B, Rishniw M, Weitzman G, Bosworth B, Yantiss R, Orsi RH, Wiedmann M, McDonough P, Kim SG, Berg D, Schukken Y, Scherl E, Simpson KW (2007). "Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum". The ISME Journal 1 (5): 403–18.  
  71. ^ Sasaki M, Sitaraman SV, Babbin BA, Gerner-Smidt P, Ribot EM, Garrett N, Alpern JA, Akyildiz A, Theiss AL, Nusrat A, Klapproth JM (2007). "Invasive Escherichia coli are a feature of Crohn's disease". Laboratory investigation; a journal of technical methods and pathology 87 (10): 1042–54.  
  72. ^ Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich N, Bringer MA, Swidsinski A, Beaugerie L, Colombel JF (2004). "High prevalence of Adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease". Gastroenterology 127 (2): 412–21.  
  73. ^ Baumgart M, Dogan B, Rishniw M, Weitzman G, Bosworth B, Yantiss R, Orsi RH, Wiedmann M, McDonough P, Kim SG, Berg D, Schukken Y, Scherl E, Simpson KW (2007). "Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum". The ISME journal ( 
  74. ^ Nickerson KP, McDonald C (2012). Mizoguchi, Emiko, ed. "Crohn's Disease-Associated Adherent-Invasive Escherichia coli Adhesion is Enhanced by Exposure to the Ubiquitous Dietary Polysaccharide Maltodextrin". PLoS ONE ( 
  75. ^ Martinez-Medina M, Naves P, Blanco J, Aldeguer X, Blanco JE, Blanco M, Ponte C, Soriano F, Darfeuille-Michaud A, Garcia-Gil LJ (2009). "Biofilm formation as a novel phenotypic feature of adherent-invasive Escherichia coli (AIEC)". BMC Microbiology 9: 202.  
  76. ^ Chargui A, Cesaro A, Mimouna S, Fareh M, Brest P, Naquet P, Darfeuille-Michaud A, Hébuterne X, Mograbi B, Vouret-Craviari V, Hofman P (2012). "Subversion of autophagy in adherent invasive Escherichia coli-infected neutrophils induces inflammation and cell death". PLoS ONE 7 (12): e51727.  
  77. ^ Craven M, Egan CE, Dowd SE, McDonough SP, Dogan B, Denkers EY, Bowman D, Scherl EJ, Simpson KW (2012). "Inflammation drives dysbiosis and bacterial invasion in murine models of ileal Crohn's disease". PLoS ONE 7 (7): e41594.  
  78. ^ Barnich N, Darfeuille-Michaud A (January 2007). "Adherent-invasive Escherichia coli and Crohn's disease". Current Opinion in Gastroenterology 23 (1): 16–20.  
  79. ^ Cenac N, Andrews CN, Holzhausen M, Chapman K, Cottrell G, Andrade-Gordon P, Steinhoff M, Barbara G, Beck P, Bunnett NW, Sharkey KA, Ferraz JG, Shaffer E, Vergnolle N (March 2007). "Role for protease activity in visceral pain in irritable bowel syndrome". J. Clin. Invest. 117 (3): 636–47.  
  80. ^ Cenac N, Coelho AM, Nguyen C, Compton S, Andrade-Gordon P, MacNaughton WK, Wallace JL, Hollenberg MD, Bunnett NW, Garcia-Villar R, Bueno L, Vergnolle N (November 2002). "Induction of Intestinal Inflammation in Mouse by Activation of Proteinase-Activated Receptor-2". Am. J. Pathol. 161 (5): 1903–15.  
  81. ^ Boorom KF, Smith H, Nimri L, Viscogliosi E, Spanakos G, Parkar U, Li LH, Zhou XN, Ok UZ, Leelayoova S, Jones MS (October 2008). "Oh my aching gut: irritable bowel syndrome, Blastocystis, and asymptomatic infection". Parasit Vectors 1 (1): 40.  
  82. ^ Hugot JP, Alberti C, Berrebi D, Bingen E, Cézard JP (2003). "Crohn's disease: the cold chain hypothesis". Lancet 362 (9400): 2012–5.  
  83. ^ "Fridges blamed for Crohn's disease rise". Medical News Today. 2003-12-12. 
  84. ^ Forbes A, Kalantzis T (2005). "Crohn's disease: The cold chain hypothesis". International Journal of Colorectal Disease 21 (5): 399–401.  
  85. ^ Subramanian S, Roberts CL, Hart CA, Martin HM, Edwards SW, Rhodes JM, Campbell BJ (2007). "Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics". Antimicrobial Agents and Chemotherapy 52 (2): 427–34.  
  86. ^ Mpofu CM, Campbell BJ, Subramanian S, Marshall-Clarke S, Hart CA, Cross A, Roberts CL, McGoldrick A, Edwards SW, Rhodes JM (2007). "Microbial Mannan Inhibits Bacterial Killing by Macrophages: A Possible Pathogenic Mechanism for Crohn's Disease". Gastroenterology 133 (5): 1487–98.  
  87. ^ "New insights into Crohn's Disease". 
  88. ^ "Possible links between Crohn's disease and Paratuberculosis". European Commission Directorate-General Health & Consumer Protection. Retrieved 2009-11-07. 
  89. ^ Gui GP, Thomas PR, Tizard ML, Lake J, Sanderson JD, Hermon-Taylor J (1997). "Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics".  
  90. ^ a b Shoda R, Matsueda K, Yamato S, Umeda N (1996). "Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan". The American journal of clinical nutrition 63 (5): 741–5.  
  91. ^ Lesko SM, Kaufman DW, Rosenberg L, Helmrich SP, Miller DR, Stolley PD, Shapiro S (1985). "Evidence for an increased risk of Crohn's disease in oral contraceptive users". Gastroenterology 89 (5): 1046–9.  
  92. ^ Reddy D, Siegel CA, Sands BE, Kane S (July 2006). "Possible association between isotretinoin and inflammatory bowel disease". The American journal of gastroenterology 101 (7): 1569–73.  
  93. ^ Borobio E, Arín A, Valcayo A, Iñarrairaegui M, Nantes O, Prieto C (2004). "[Isotretinoin and ulcerous colitis]". An Sist Sanit Navar (in Spanish; Castilian) 27 (2): 241–3.  
  94. ^ Reniers DE, Howard JM (October 2001). "Isotretinoin-induced inflammatory bowel disease in an adolescent". Annals of Pharmacotherapy 35 (10): 1214–6.  
  95. ^ "Crohn's Disease". National Digestive Diseases Information Clearinghouse. Retrieved 13 November 2012. 
  96. ^ Lomer MC, Hutchinson C, Volkert S, Greenfield SM, Catterall A, Thompson RP, Powell JJ (December 2004). "Dietary sources of inorganic microparticles and their intake in healthy subjects and patients with Crohn's disease". Br. J. Nutr. 92 (6): 947–55.  
  97. ^ Powell JJ, Thoree V, Pele LC (October 2007). "Dietary microparticles and their impact on tolerance and immune responsiveness of the gastrointestinal tract". Br. J. Nutr. 98 Suppl 1: S59–63.  
  98. ^ Crawford JM. "The Gastrointestinal tract, Chapter 17". In Cotran RS, Kumar V, Robbins SL. Robbins Pathologic Basis of Disease: 5th Edition. W.B. Saunders and Company, Philadelphia, 1994.
  99. ^
  100. ^ HCP: Pill Cam, Capsule Endoscopy, Esophageal Endoscopy
  101. ^ Scheinfeld NS, Teplitz E, McClain SA (November 2001). "Crohn's disease and lichen nitidus: a case report and comparison of common histopathologic features". Inflammatory Bowel Diseases 7 (4): 314–8.  
  102. ^ Tan, WC.; Allan, RN. (Oct 1993). "Diffuse jejunoileitis of Crohn's disease.". Gut 34 (10): 1374–8.  
  103. ^ a b Gasche C, Scholmerich J, Brynskov J, D'Haens G, Hanauer SB, Irvine EJ, Jewell DP, Rachmilewitz D, Sachar DB, Sandborn WJ, Sutherland LR (2007). "A simple classification of Crohn's disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998". Inflammatory Bowel Diseases 6 (1): 8–15.  
  104. ^ Dubinsky MC, Fleshner PP (2003). "Treatment of Crohn's disease of inflammatory, stenotic, and fistulizing phenotypes". Current Treatment Options in Gastroenterology 6 (3): 183–200.  
  105. ^ a b Hara AK, Leighton JA, Heigh RI, Sharma VK, Silva AC, De Petris G, Hentz JG, Fleischer DE (2005). "Crohn Disease of the Small Bowel: Preliminary Comparison among CT Enterography, Capsule Endoscopy, Small-Bowel Follow-through, and Ileoscopy". Radiology 238 (1): 128–34.  
  106. ^ Triester SL, Leighton JA, Leontiadis GI, Gurudu SR, Fleischer DE, Hara AK, Heigh RI, Shiff AD, Sharma VK (2006). "A meta-analysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with non-stricturing small bowel Crohn's disease". The American Journal of Gastroenterology 101 (5): 954–64.  
  107. ^ Dixon PM, Roulston ME, Nolan DJ; Roulston; Nolan (1993). "The small bowel enema: A ten year review". Clinical Radiology 47 (1): 46–8.  
  108. ^ Carucci LR, Levine MS; Levine (2002). "Radiographic imaging of inflammatory bowel disease". Gastroenterology Clinics of North America 31 (1): 93–117, ix.  
  109. ^ Rajesh A, Maglinte DD; Maglinte (2006). "Multislice CT enteroclysis: technique and clinical applications". Clinical Radiology 61 (1): 31–9.  
  110. ^ Zissin R, Hertz M, Osadchy A, Novis B, Gayer G; Hertz; Osadchy; Novis; Gayer (2005). "Computed Tomographic Findings of Abdominal Complications of Crohn's Disease—Pictorial Essay" (PDF). Canadian Association of Radiologists Journal 56 (1): 25–35.  
  111. ^ Mackalski BA, Bernstein CN; Bernstein (2005). "New diagnostic imaging tools for inflammatory bowel disease". Gut 55 (5): 733–41.  
  112. ^ Goh J, O'Morain CA; O'Morain (2003). "Nutrition and adult inflammatory bowel disease". Alimentary Pharmacology and Therapeutics 17 (3): 307–20.  
  113. ^ Chamouard P, Richert Z, Meyer N, Rahmi G, Baumann R; Richert; Meyer; Rahmi; Baumann (2006). "Diagnostic Value of C-Reactive Protein for Predicting Activity Level of Crohn's Disease". Clinical Gastroenterology and Hepatology 4 (7): 882–7.  
  114. ^ Kaila B, Orr K, Bernstein CN; Orr; Bernstein (2005). "The anti-Saccharomyces cerevisiae antibody assay in a province-wide practice: accurate in identifying cases of Crohn's disease and predicting inflammatory disease". The Canadian Journal of Gastroenterology 19 (12): 717–21.  
  115. ^ Israeli E, Grotto I, Gilburd B, Balicer RD, Goldin E, Wiik A, Shoenfeld Y; Grotto; Gilburd; Balicer; Goldin; Wiik; Shoenfeld (2005). "Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease". Gut 54 (9): 1232–6.  
  116. ^ Ferrante M, Henckaerts L, Joossens M, Pierik M, Joossens S, Dotan N, Norman GL, Altstock RT, Van Steen K, Rutgeerts P, Van Assche G, Vermeire S; Henckaerts; Joossens; Pierik; Joossens; Dotan; Norman; Altstock; Van Steen; Rutgeerts; Van Assche; Vermeire, S (2007). "New serological markers in inflammatory bowel disease are associated with complicated disease behaviour". Gut 56 (10): 1394–403.  
  117. ^ Papp M, Altorjay I, Dotan N, Palatka K, Foldi I, Tumpek J, Sipka S, Udvardy M, Dinya T, Lakatos L, Kovacs A, Molnar T, Tulassay Z, Miheller P, Norman GL, Szamosi T, Papp J, Lakatos PL; Altorjay; Dotan; Palatka; Foldi; Tumpek; Sipka; Udvardy; Dinya; Lakatos; Kovacs; Molnar; Tulassay; Miheller; Norman; Szamosi; Papp; Hungarian Ibd Study; Lakatos (2008). "New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort". The American Journal of Gastroenterology 103 (3): 665–81.  
  118. ^ Seow CH, Stempak JM, Xu W, Lan H, Griffiths AM, Greenberg GR, Steinhart AH, Dotan N, Silverberg MS; Stempak; Xu; Lan; Griffiths; Greenberg; Steinhart; Dotan; Silverberg (2009). "Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype". Am J Gastroenterol 104 (6): 1426–34.  
  119. ^ Dotan I (2007). "Serologic markers in inflammatory bowel disease: tools for better diagnosis and disease stratification". Expert Rev Gastroenterol Hepatol 1 (2): 265–74.  
  120. ^ Broomé U, Bergquist A (February 2006). "Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer". Seminars in Liver Disease 26 (1): 31–41.  
  121. ^ Baumgart DC, Sandborn WJ (May 2007). "Inflammatory bowel disease: clinical aspects and established and evolving therapies.". The Lancet 369 (9573): 1641–57.  
  122. ^ Shepherd NA (August 2002). "Granulomas in the diagnosis of intestinal Crohn's disease: a myth exploded?". Histopathology 41 (2): 166–8.  
  123. ^ Mahadeva U, Martin JP, Patel NK, Price AB (July 2002). "Granulomatous ulcerative colitis: a re-appraisal of the mucosal granuloma in the distinction of Crohn's disease from ulcerative colitis". Histopathology 41 (1): 50–5.  
  124. ^ a b Pages 152-156 (Section: Inflammatory bowel disease(IBD)) in: Elizabeth D Agabegi; Agabegi, Steven S. (2008). Step-Up to Medicine (Step-Up Series). Hagerstwon, MD: Lippincott Williams & Wilkins.  
  125. ^ Feller M, Huwiler K, Schoepfer A, Shang A, Furrer H, Egger M (2010). "Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials". Clin. Infect. Dis. 50 (4): 473–80.  
  126. ^ [1] Section "Antibiotics and Ulcerative Colitis" in: Prantera C, Scribano ML (2009). "Antibiotics and probiotics in inflammatory bowel disease: why, when, and how". Curr. Opin. Gastroenterol. 25 (4): 329–33.  
  127. ^ a b Fries, WS; Nazario, B (2007-05-16). "Crohn's Disease: 54 Tips to Help You Manage".  
  128. ^ Escott-Stump, Sylvia (2008). Nutrition and Diagnosis-Related Care, 7th edition. Baltimore, MD: Lippincott Williams & Wilkins. pp. 1020 (pp 431).  
  129. ^ Shanahan, Fergus (1 January 2002). "Crohn's disease". The Lancet 359 (9300): 62–69.  
  130. ^ "FDA Approves Cimzia to Treat Crohn's Disease" (Press release).  
  131. ^ Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P; Colombel; Enns; Feagan; Hanauer; Lawrance; Panaccione; Sanders; Schreiber; Targan; Van Deventer; Goldblum; Despain; Hogge; Rutgeerts; International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group (2005). "Natalizumab Induction and Maintenance Therapy for Crohn's Disease". New England Journal of Medicine 353 (18): 1912–25.  
  132. ^ MacDonald JK, McDonald JW; McDonald (2007). MacDonald, John K, ed. "Natalizumab for induction of remission in Crohn's disease". Cochrane Database of Systematic Reviews (1): CD006097.  
  133. ^ Longmore, Murray; Ian Wilkinson; Tom Turmezei; Chee Kay Cheung (2007). Oxford Handbook of Clinicial Medicine (7th ed.). Oxford University Press. pp. 266–7.  
  134. ^ Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, Mitton S, Orchard T, Rutter M, Younge L, Lees C, Ho GT, Satsangi J, Bloom S; Cole; Windsor; Ahmad; Arnott; Driscoll; Mitton; Orchard; Rutter; Younge; Lees; Ho; Satsangi; Bloom; IBD Section of the British Society of Gastroenterology (May 2011). "Guidelines for the management of inflammatory bowel disease in adults". Gut 60 (5): 571–607.  
  135. ^ a b c Goddard AF, James MW, McIntyre AS, Scott BB; James; McIntyre; Scott; British Society of Gastroenterology (2011). "Guidelines for the management of iron deficiency anaemia". Gut 60 (10): 1309–1316.  
  136. ^ a b Inflamm Bowel Dis Volume 13, Number 12, December 2007
  137. ^ Tresca, AJ (2007-01-12). "Resection Surgery for Crohn's Disease".  
  138. ^ Ozuner G, Fazio VW, Lavery IC, Milsom JW, Strong SA; Fazio; Lavery; Milsom; Strong (1996). "Reoperative rates for Crohn's disease following strictureplasty. Long-term analysis". Dis. Colon Rectum 39 (11): 1199–203.  
  139. ^ Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M; Geboes; Vantrappen; Beyls; Kerremans; Hiele (October 1990). "Predictability of the postoperative course of Crohn's disease". Gastroenterology 99 (4): 956–63.  
  140. ^ Yamamoto T, Bamba T, Umegae S, Matsumoto K; Bamba; Umegae; Matsumoto (August 2013). "The impact of early endoscopic lesions on the clinical course of patients following ileocolonic resection for Crohn's disease: A 5-year prospective cohort study". United European Gastroenterol J 1 (4): 294–8.  
  141. ^ Short Bowel Syndrome as defined by the National Institute of Diabetes and Digestive and Kidney Diseases
  142. ^ Hofmann AF (1967). "The syndrome of ileal disease and the broken enterohepatic circulation: cholerhetic enteropathy.". Gastroenterology 52 (4): 752–7.  
  143. ^ Rhodes, M (2006-10-24). "Intestinal transplant for Crohn's disease". Everyday Health. Retrieved 2009-03-22. 
  144. ^ Caprilli R, Gassull MA, Escher JC, Moser G, Munkholm P, Forbes A, Hommes DW, Lochs H, Angelucci E, Cocco A, Vucelic B, Hildebrand H, Kolacek S, Riis L, Lukas M, de Franchis R, Hamilton M, Jantschek G, Michetti P, O'Morain C, Anwar MM, Freitas JL, Mouzas IA, Baert F, Mitchell R, Hawkey CJ; Gassull; Escher; Moser; Munkholm; Forbes; Hommes; Lochs; Angelucci; Cocco; Vucelic; Hildebrand; Kolacek; Riis; Lukas; De Franchis; Hamilton; Jantschek; Michetti; O'Morain; Anwar; Freitas; Mouzas; Baert; Mitchell; Hawkey; European Crohn's Colitis Organisation (2006). "European evidence based consensus on the diagnosis and management of Crohn's disease: special situations". Gut. 55 Suppl 1 (Suppl 1): i36–58.  
  145. ^ "Use of complementary and alternative medicine in Germany – a survey of patients with inflammatory bowel disease". BioMed Central. Retrieved 21 September 2010. At the same time, further clinical studies assessing the most commonly used CAM therapies are urgently needed. Research in CAM offers the chance to discover new treatment options in the management of IBD but may also protect patients from ineffective and expensive 'pseudo'-therapies. 
  146. ^ Joos S, Brinkhaus B, Maluche C, Maupai N, Kohnen R, Kraehmer N, Hahn EG, Schuppan D; Brinkhaus; Maluche; Maupai; Kohnen; Kraehmer; Hahn; Schuppan (2004). "Acupuncture and moxibustion in the treatment of active Crohn's disease: a randomized controlled study". Digestion 69 (3): 131–9.  
  147. ^ Caprilli R, Gassull MA, Escher JC, Moser G, Munkholm P, Forbes A, Hommes DW, Lochs H, Angelucci E, Cocco A, Vucelic B, Hildebrand H, Kolacek S, Riis L, Lukas M, de Franchis R, Hamilton M, Jantschek G, Michetti P, O'Morain C, Anwar MM, Freitas JL, Mouzas IA, Baert F, Mitchell R, Hawkey CJ; Gassull; Escher; Moser; Munkholm; Forbes; Hommes; Lochs; Angelucci; Cocco; Vucelic; Hildebrand; Kolacek; Riis; Lukas; De Franchis; Hamilton; Jantschek; Michetti; O'Morain; Anwar; Freitas; Mouzas; Baert; Mitchell; Hawkey; European Crohn's Colitis Organisation (2006). "The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations". Gut 55 (Suppl 1): i36–i58.  
  148. ^ Ernst, E.; Lee, Myeong Soo; Choi, Tae-Young (2011). "Acupuncture: Does it alleviate pain and are there serious risks? A review of reviews" (PDF). Pain 152 (4): 755–764.  
  149. ^ Smart HL, Mayberry JF, Atkinson M; Mayberry; Atkinson (1986). "Alternative medicine consultations and remedies in patients with the irritable bowel syndrome". Gut 27 (7): 826–8.  
  150. ^ "Crohn's disease - Prognosis". University of Maryland Medical Centre. Retrieved 19 October 2012. 
  151. ^ Canavan C, Abrams KR, Mayberry J; Abrams; Mayberry (2006). "Meta-analysis: Colorectal and small bowel cancer risk in patients with Crohn's disease". Alimentary Pharmacology and Therapeutics 23 (8): 1097–104.  
  152. ^ Greenstein AJ, Janowitz HD, Sachar DB (September 1976). "The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients". Medicine (Baltimore) 55 (5): 401–12.  
  153. ^ Enterovesical Fistula at eMedicine
  154. ^ Ekbom A, Helmick C, Zack M, Adami HO; Helmick; Zack; Adami (1990). "Increased risk of large-bowel cancer in Crohn's disease with colonic involvement". Lancet 336 (8711): 357–9.  
  155. ^ Collins PD, Mpofu C, Watson AJ, Rhodes JM; Mpofu; Watson; Rhodes (2006). Watson, Alastair J, ed. "Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease". Cochrane Database Syst Rev (2): CD000279.  
  156. ^ Zisman TL, Rubin DT; Rubin (2008). "Colorectal cancer and dysplasia in inflammatory bowel disease". World Journal of Gastroenterology 14 (17): 2662–9.  
  157. ^ Evans JP, Steinhart AH, Cohen Z, McLeod RS; Steinhart; Cohen; McLeod (2003). "Home Total Parenteral Nutrition an Alternative to Early Surgery for Complicated Inflammatory Bowel Disease". Journal of Gastrointestinal Surgery 7 (4): 562–6.  
  158. ^ "Complications of Crohn's Disease". Centocor Ortho Biotech. Retrieved 2009-11-07. 
  159. ^ Carrillo, Maria (September 1, 1985). "Man of Many Problems Comes to City for Help". Richmond Times-Dispatch (Richmond, Virginia, USA). p. B1. 
  160. ^ "Kay, Laura Lynn". Richmond Times-Dispatch (Richmond, Virginia, USA). April 3, 2014. 
    Loebenberg, Priscilla (March 2, 2014). "Doris L. Johnson, 82, of Westminster". Carroll County Times (Westminster, Maryland, USA). 
    Berrier Jr., Ralph (December 31, 2013). "In memoriam: Dan Hodges Jr.". The Roanoke Times (Roanoke, Virginia, USA). 
    "Cynthia Meredith Routt". Daily Press (Newport News, Virginia, USA). May 4, 2014. p. A11. 
  161. ^ Kaplan, C (2005-10-21). "IBD and Pregnancy: What You Need to Know".  
  162. ^ a b Hiatt RA, Kaufman L; Kaufman (1988). "Epidemiology of inflammatory bowel disease in a defined northern California population". Western Journal of Medicine 149 (5): 541–6.  
  163. ^ Moum B, Vatn MH, Ekbom A, Aadland E, Fausa O, Lygren I, Stray N, Sauar J, Schulz T; Vatn; Ekbom; Aadland; Fausa; Lygren; Stray; Sauar; Schulz (1996). "Incidence of Crohn's disease in four counties in southeastern Norway, 1990-93. A prospective population-based study. The Inflammatory Bowel South-Eastern Norway (IBSEN) Study Group of Gastroenterologists". Scandinavian Journal of Gastroenterology 31 (4): 355–61.  
  164. ^ Shivananda S, Lennard-Jones J, Logan R, Fear N, Price A, Carpenter L, van Blankenstein M; Lennard-Jones; Logan; Fear; Price; Carpenter; Van Blankenstein (1996). "Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD)". Gut 39 (5): 690–7.  
  165. ^ Yang H, McElree C, Roth MP, Shanahan F, Targan SR, Rotter JI; McElree; Roth; Shanahan; Targan; Rotter (1993). "Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews". Gut 34 (4): 517–24.  
  166. ^ Seksik P, Nion-Larmurier I, Sokol H, Beaugerie L, Cosnes J; Nion-Larmurier; Sokol; Beaugerie; Cosnes (2009). "Effects of light smoking consumption on the clinical course of Crohn's disease". Inflamm. Bowel Dis. 15 (5): 734–41.  
  167. ^ "Crohn's disease manifests differently in boys and girls".  
  168. ^ "Who is affected by Crohn's disease". Healthwise. 
  169. ^ Satsangi J, Jewell DP, Bell JI; Jewell; Bell (1997). "The genetics of inflammatory bowel disease". Gut 40 (5): 572–4.  
  170. ^ Tysk C, Lindberg E, Järnerot G, Flodérus-Myrhed B; Lindberg; Järnerot; Flodérus-Myrhed (1988). "Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking". Gut 29 (7): 990–6.  
  171. ^ Kirsner JB (1988). "Historical aspects of inflammatory bowel disease". J. Clin. Gastroenterol. 10 (3): 286–97.  
  172. ^ Lichtarowicz, A.M.; Mayberry, J.F. (August 1, 1988). "Antoni Lésniowski and his contribution to regional enteritis (Crohn's disease)". Journal of the Royal Society of Medicine 81 (8): 468–470.  
  173. ^ a b Agrawal G, Borody TJ, Chamberlin W; Borody; Chamberlin (2014). "'Global warming' to Mycobacterium avium subspecies paratuberculosis". Future Microbiology 9 (7): 829–832.  
  174. ^ Scribano, ML; Prantera, C (Feb 7, 2013). "Use of antibiotics in the treatment of Crohn's disease.". World journal of gastroenterology : WJG 19 (5): 648–53.  
  175. ^ Chamberlin, W; Borody, TJ; Campbell, J (Nov 2011). "Primary treatment of Crohn's disease: combined antibiotics taking center stage.". Expert review of clinical immunology 7 (6): 751–60.  
  176. ^ Bull TJ, Gilbert SC, Sridhar S, Linedale R, Dierkes N, Sidi-Boumedine K, Hermon-Taylor J; Gilbert; Sridhar; Linedale; Dierkes; Sidi-Boumedine; Hermon-Taylor (2007). A novel multi-antigen virally vectored vaccine against Mycobacterium avium subspecies paratuberculosis"'". PLoS ONE 2 (11): e1229.  
  177. ^ Hultén, K.; Almashhrawi, A.; El-Zaatari, FA.; Graham, DY. (Mar 2000). "Antibacterial therapy for Crohn's disease: a review emphasizing therapy directed against mycobacteria". Dig Dis Sci 45 (3): 445–56.  
  178. ^ Croese J, O'neil J, Masson J, Cooke S, Melrose W, Pritchard D, Speare R; O'Neil; Masson; Cooke; Melrose; Pritchard; Speare (2006). "A proof of concept study establishing Necator americanus in Crohn's patients and reservoir donors". Gut 55 (1): 136–7.  
  179. ^ *Massa F, Monory K; Monory (2007). "Endocannabinoids and the gastrointestinal tract". Journal of Endocrinological Investigation 29 ((Suppl)): 47–57.  
  180. ^ Massa F, Storr M, Lutz B; Storr; Lutz (2005). "The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract". Journal of Molecular Medicine 83 (12): 944–54.  
  181. ^ Izzo AA, Coutts AA; Coutts (2005). "Cannabinoids and the digestive tract". Handbook of Experimental Pharmacology. Handbook of Experimental Pharmacology 168 (168): 573–98.  
  182. ^ Srinivasan, R; Akobeng, AK (Apr 15, 2009). "Thalidomide and thalidomide analogues for induction of remission in Crohn's disease.". The Cochrane database of systematic reviews (2): CD007350.  
  183. ^ Akobeng, AK; Stokkers, PC (Apr 15, 2009). "Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease.". The Cochrane database of systematic reviews (2): CD007351.  

External links

  • Crohn's disease at DMOZ
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.